← All compounds

DSIP

Delta Sleep-Inducing Peptide · 10mg vial
A$ 258Rp 2.900.000
Bulk buy pricing
3–5 vials
A$ 236
Save ~9%
6–9 vials
A$ 222
Save ~13%
10+ vials
A$ 200
Save ~22%

Studied for deep-sleep support, stress-hormone (cortisol) regulation, and recovery in cycles where standard sleep approaches have reached their ceiling.

Compound overview

What it is

DSIP (Delta Sleep-Inducing Peptide) is a neuropeptide originally isolated from rabbit thalamus in 1977. It modulates hypothalamic-pituitary-adrenal (HPA) axis activity — reducing basal cortisol secretion and normalising the cortisol rhythm. It increases slow-wave (delta) sleep proportion and stabilises sleep architecture. It also has antioxidant properties and modulates catecholamine (dopamine, noradrenaline) biosynthesis. The peptide does not induce immediate sedation but normalises sleep architecture over a treatment course.

Slow-wave sleep (the most physically restorative sleep stage) increases. Cortisol normalises — both basal levels and the disrupted rhythms common in chronic stress. Sleep latency (time to fall asleep) decreases. Users report deeper, more restorative sleep and improved recovery from physical and cognitive stress over a cycle. Morning fatigue reduces as slow-wave sleep proportion increases.

Studied outcomes
  • Increased delta (slow-wave) sleep proportion in EEG studies
  • Cortisol reduction and HPA axis normalisation
  • Improved sleep architecture and reduced sleep latency
  • Antioxidant properties in central nervous system tissue
  • Clinical use in pain syndromes — reduces opioid withdrawal symptoms
Suitability

Who it's for

  • Chronic poor sleep where standard interventions have been exhausted
  • High cortisol or disrupted stress hormone rhythms
  • Recovery from adrenal fatigue, burnout, or overtraining
  • Optimising the sleep stage where physical recovery and GH release occur
Who should avoid it
  • Pregnancy
  • Those seeking immediate sedation — DSIP normalises sleep architecture rather than inducing sedation
  • Acute insomnia without cortisol dysregulation (simpler interventions may suffice)
Dosing guidance

Protocol guidance

Dose
100–300mcg per night
Frequency
Once nightly, 3–5 nights per week
Cycle length
2–4 weeks; effects often persist beyond the cycle
Route
Subcutaneous injection
Timing
30–60 minutes before intended sleep time
Safety

Contraindications & cautions

  • Not a sedative — do not expect immediate knockdown effect
  • Some users report transient vivid dreams as sleep architecture normalises
  • Well-tolerated in clinical studies; adverse effect profile appears low
  • Cortisol reduction — monitor in those on HPA-related medications
Stacking

Pairs well with

DSIP optimises night recovery; Semax optimises daytime cognition — a complete sleep/wake protocol

Selank reduces pre-sleep anxiety; DSIP deepens the architecture of sleep that follows

GH secretagogue peaks during slow-wave sleep — DSIP increases that stage, amplifying GH release

Evidence base

Research

Monnier et al. (1977) — Original DSIP isolation and characterisation ↗Sudakov et al. (2011) — DSIP and stress resilience review ↗

Not medical advice. Not a substitute for medical care. Consult your licensed practitioner before beginning any protocol. Peptides are sold for research purposes only and are suitable for adults aged 18 years and over.